Dr. Wei Chen, CEO

Dr. Chen has 30 years of experience in the establishment of large-scale industrialization platforms, quality management, and new drug declaration for international biopharmaceutical companies including Bristol Myers Squibb, Johnson & Johnson, Pfizer, and Merck. He has a Ph.D. in Bioreactor Engineering from Nagoya University, Japan. He is also a Postdoctoral Fellow at UCLA, University of British Columbia Medical School, and Yale University Medical School.

Previously responsible for new drug development and industrialization of various new biological drug development, Dr. Chen has experience in the establishment and listing of multiple biomedical companies, participated in the creation of the internationally renowned CDMO company BioReliance, and is responsible for operation management. Dr. Chen is a member of the International Society of Industrial Microbiology, the founder of the Microbiome Society and the International Biopharmaceutical Engineering Alliance.

Dr. Jianmin Fang, Chairman

Dr. Fang has a Ph.D. from Dalhousie University, Canada, and post-doctoral fellow at Harvard Medical School, working in the United States for many years on biopharmaceutical research and development. He is a member of the Taishan Scholars program in Shandong Province, a member of the National Expert Group on Major New Drug Creation, professor and doctoral tutor of Tongji University and the Dean of Suzhou Research Institute of Tongji University. Dr. Fang’s research results have been published in several journals including Natural Biotechnology, Journal of the Americal Academy of Sciences, and Oncology Research, with more than 30 invention patents, and many projects have achieved transformation. He is the inventor and designer of Conbercept. He is a member of the China Pharmaceutical  Association, the Deputy Chairman of the Malonal Antibody Professional Committee of the China Pharmaceutical Innovation Promotion Association. He has won the second prize of the National Science and Technology Progress Award, Chinese Overseas Chinese Contribution Award, and China Industry-University-Research Cooperation Innovation Award.

Dr. Lifang He, Global VP, BD and Marketing

Dr. He has a Ph.D. and is a postdoctoral fellow in pharmacology from Einstein College of Medicine, USA and MBA from City University of New York. He has been engaged in customer development and business development for a long time in the United States, successfully promoted the business growth of many internationally renowned CDMO companies, and has extensive experience in marketing and product listing. Dr. He has published more than 20 scientific articles.

Dr. Changjiang Huang, Chief Scientific Officer

Dr. Huang has a Ph.D. from Iowa State University, completed postdoctoral research in reproductive physiology at the University of Southern California and neuroendocrinology at the University of California, Los Angeles. He is one the first scholars to carry out research on ADC new drugs and has achieved results, and is a special expert of Taishan Scholar program in Shandong Province. He has been engaged in biomedical research and development for more than 30 years and has published hundreds of papers in academic journals such as Diabetes, Biochemistry, and Neuroscience. Member of the American Society of Cell Biology, member of the International Neurochemical Society, member of the American Diabetes Association, and member of the American Association for the Advancement of Science.

Dr. Li has a Ph.D. in Molecular Biology and Biochemistry from Peking University, postdoctoral researcher at Harvard Medical School, a member of the Biophorum Operations Group, a virus removal validation group, and an expert in virus removal research for antibody downstream processes. She has extensive experience in CMC and CMO management and has participated in the process characterization and commercial production verification of several mAb and ADC projects. She has worked for more than ten years in the world’s first company to engage in the development of new ADC drugs. She has served as the Chief Scientist, the head of the process development department, and the leader of the drug-making evaluation team for new drugs. Having both applied for IND in the US and Europe, of which seven are self-developed new drugs and six are developed in cooperation with internationally renowned pharmaceutical companies for the development of CRO / CMO projects. Among them, T-DM1, the first in the world to treat HER2-positive breast cancer, was approved by the FDA in 2013. Initiated a new one-step coupling production process, led the team to overcome the technical problems of ADC coupled polymers and unconjugated naked antibodies with high content and improved the coupling efficiency. Participated in publishing several virus removal verification papers.

Dr. Wu Yongjian, Chief Operating Officer

Dr. Yongjian has a Ph.D. in immunology from the University of Toronto, Canada, a postdoctoral fellow in neurobiology at Standford University. He has nearly 20 years of working experience in the biopharmaceutical industry and has been engaged in R&D and management of well-known pharmaceutical companies such as Bayer and Genentech. He has extensive experience in the research and development of protein therapy (biological agents, including monoclonal antibodies, ADCs, and biosimilars), and is particularly good at the technology and management of CMC development such as protein engineering, cell line development, biological detection, and protein chemistry.

Dr. Lou Zhigang, Vice President of Quality

Dr. Zhigang has an MBA from the Kelley School of Business, Indiana University, and an MS in Chemistry from the University of Louisville. He has accumulated more than 20 years of pharmaceutical production quality management experience in well-known pharmaceutical companies such as Abbott, Eli Lilly, Amgen, Wuming Bio. Proficient in quality compliance operations under the requirements of the US FDA, Chinese NMPA and ICH laws and regulations, especially with a deep understanding of the phase adaptability of GMP can be effectively used. Presided over the establishment and improvement of the company’s quality system multiple times. Facility verification, including the release of many clinical and marketed products.

Dr. Lorne Babiuk, Scientific Advisor

Dr. Babiuk is a fellow of the Royal Society of Canada and Fellow of the European Academy of Sciences. He holds 42 patents, part-time positions in the editorial boards of more than 40 international scientific organizations and science and technology journals, invited reviewer of 16 science and technology magazines and members of the board of directors of more than 20 biotechnology companies. He has won 57 awards, including the Queen Elizabeth II Diamond Commemorative Media, The Canadian Arts Council Award, the 2016 China GCHERA World Agriculture Award, and more than 20 “1000 International Scientific Leaders” and “World Health Science Leaders” awards.